News from sutro biopharma A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Jan 03, 2019, 16:05 ET Sutro to Present at 37th Annual J.P. Morgan Healthcare Conference

Sutro Biopharma, Inc. (NASDAQ: STRO) today announced that Bill Newell, Chief Executive Officer, will present at the 37th Annual J.P. Morgan...


Oct 12, 2018, 07:00 ET Sutro's STRO-001 Receives U.S. FDA Orphan Drug Designation for Treatment of Multiple Myeloma

Sutro Biopharma, Inc. (NASDAQ: STRO), has been granted Orphan Drug Designation by the United States Food and Drug Administration (FDA) for STRO-001...


Jul 26, 2018, 10:45 ET Sutro Biopharma Announces $85.4 Million Series E Round

Sutro Biopharma, Inc., has secured $85.4 million in Series E financing to advance its wholly-owned pipeline of novel cancer therapeutics, including...


Jul 24, 2018, 08:00 ET Sutro Biopharma Collaborates with Merck to Develop Therapeutics for Cancer and Autoimmune Disorders

Sutro Biopharma, Inc., has signed a collaboration and licensing agreement with Merck, known as MSD outside the United States and Canada, to discover...


Apr 26, 2018, 08:00 ET Sutro Initiates First Clinical Trial of CD74-Targeting ADC for Lymphoma & Multiple Myeloma Treatment; The First of a New Generation of Precisely Engineered ADCs

Sutro Biopharma, Inc. has begun dosing patients in its initial clinical trial of its potential first-in-class antibody drug conjugate, or ADC,...


Apr 16, 2018, 06:30 ET Sutro ADC Effectively Targets Folate Receptor Alpha in Ovarian Cancer Preclinical Research

Sutro Biopharma's first antibody drug conjugate (ADC) to treat solid tumors was highly effective against ovarian cancer in preclinical xenograft...


Dec 12, 2017, 07:00 ET Sutro Antibody Effectively Targets CD74 in Lymphoma & Multiple Myeloma Preclinical Studies

Two studies presented yesterday at the American Society of Hematology's annual meeting in Atlanta showed frequent expression of CD74, a cell-surface...


Oct 11, 2017, 08:00 ET Sutro Marks Two Drug Development Milestones

Sutro Biopharma has received a manufacturing milestone payment from Celgene and has completed production of STRO-001, its first internally-developed...


Aug 10, 2017, 08:00 ET Sutro & Celgene to Refocus 2014 Immuno-Oncology Collaboration on Four Programs

Sutro Biopharma today announced it is refocusing its 2014 immuno-oncology collaboration with Celgene on four programs that are advancing through...


Jul 17, 2017, 08:00 ET New Evidence of Sutro ADC's Potency in Human Tumor Xenografts

STRO-001, Sutro Biopharma's antibody drug conjugate targeting the CD74 cell surface protein in hematologic B-cell malignancies, has been shown to...


Sep 07, 2016, 08:00 ET Sutro Marks Important Progress -- Receives Two Milestone Payments from Celgene

Sutro Biopharma Inc. today announced that it has received two milestone payments from drug discovery and development partner Celgene Corporation...


Jun 01, 2016, 08:00 ET Sutro Appoints Shabbir T. Anik Chief Technical Operations Officer

Sutro Biopharma today announced the appointment of Dr. Shabbir T. Anik to the newly-created position of chief technical operations officer. Dr. Anik...


Mar 09, 2016, 10:00 ET Sutro Expands Senior Leadership Team with Addition of Chief Medical Officer and VP of Translational Pharmacology and Preclinical Development

Sutro Biopharma today announced the appointment of Arturo Molina, M.D., M.S., FACP as chief medical officer and Mark Lupher, Ph.D., as vice president ...


Nov 18, 2015, 09:00 ET Sutro Biopharma Receives the Pantheon 2015 DiNA Outstanding Partner Award by the California Life Sciences Association

Sutro Biopharma today announced that it was awarded the Outstanding Partner Award, at the California Life Sciences Association (CLSA) annual Pantheon ...


Oct 23, 2014, 07:30 ET Sutro Biopharma and Celgene Corporation Enter Multi-Year Strategic Collaboration and Option to Acquire Agreement

Sutro Biopharma today announced it has entered into a strategic collaboration and option agreement with Celgene Corporation to discover and develop...


Sep 22, 2014, 08:00 ET FierceBiotech names Sutro Biopharma as one of its "Fierce 15" Biotech Companies of 2014

Sutro Biopharma today announced that it has been named by FierceBiotech as one of 2014's Fierce 15 biotechnology companies, designating it as one of...


Sep 17, 2014, 08:00 ET Sutro Biopharma and Merck KGaA of Darmstadt, Germany, to Partner on Development of Antibody Drug Conjugates

Sutro Biopharma, a biopharmaceutical company developing antibody drug conjugates and bispecific antibodies, and the biopharmaceutical division of...


Sep 09, 2014, 09:00 ET Sutro Biopharma to Collaborate with University of California, San Francisco (UCSF), a Recombinant Antibody Network (RAN) Member

Sutro Biopharma, a biopharmaceutical company developing a new generation of protein therapeutics, including next-generation antibody drug conjugates...


Mar 24, 2014, 09:00 ET Sutro Biopharma to Present at 21st Annual Future Leaders in the Biotech Industry Conference

Sutro Biopharma, a biopharmaceutical company developing a new generation of protein therapeutics, including next-generation antibody drug conjugates...


Jan 07, 2014, 09:00 ET Sutro Biopharma to Collaborate With Memorial Sloan-Kettering Cancer Center to Produce Bispecific Antibodies for the Treatment of Neuroblastoma

Sutro Biopharma, a biopharmaceutical company developing a new generation of protein therapeutics, including next-generation antibody drug conjugates...


Dec 11, 2013, 09:00 ET Sutro Biopharma Closes $26 Million Financing, Expands Development of Novel Immuno-Oncology Products

Sutro Biopharma today announced that the company has secured $26 million in a Series D financing. The additional financing will fund the expansion of ...


Oct 15, 2013, 02:00 ET Sutro Biopharma Presents Dual-Warhead Antibody Drug Conjugate at the World ADC Summit

Sutro Biopharma, a biopharmaceutical company developing a new generation of protein therapeutics utilizing Sutro's cell-free protein synthesis...


Jan 31, 2013, 09:00 ET Sutro Biopharma Appoints Edward C. Albini as Chief Financial Officer

Sutro Biopharma, a biopharmaceutical company developing a new generation of protein therapeutics utilizing Sutro's cell-free protein synthesis...


Jan 03, 2013, 09:00 ET Sutro Biopharma to Collaborate with Sanofi Pasteur on a Novel Production Approach for Vaccine Candidates

Sutro Biopharma, a biopharmaceutical company developing a new generation of protein therapeutics utilizing Sutro's cell-free protein synthesis...


Oct 24, 2012, 09:00 ET Sutro Biopharma Expands Senior Management Team

Sutro Biopharma, a biopharmaceutical company developing a new generation of antibody drug conjugate therapeutics and bifunctional antibody-based...